Aspergillus sensitisation: an underappreciated treatable trait in airway disease. Issue 1 (5th January 2023)

• Record Type: Journal Article
• Authors: Pollock, Jennifer; Chalmers, James D.
• Is Part Of: European respiratory journal. Volume 61:Issue 1(2023)
• Publication Date: 2023-01-05
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.02042-2022
• Languages: English
• ISSNs: 0903-1936

Abstract

In 2006, Denning et al. [1] first proposed, in the European Respiratory Journal, the term "severe asthma with fungal sensitisation (SAFS)" to describe a distinct phenotype of severe asthma characterised by an elevated IgE-mediated response towards fungal allergens. Since then, SAFS has been widely studied and is generally considered to sit within a spectrum of disease ranging from uncomplicated asthma to frank allergic bronchopulmonary aspergillosis/mycosis (ABPA/ABPM) [2, 3]. Fungal sensitisation, particularly towards Aspergillus species, has been highlighted as a potential "treatable trait" in airway disease, with anti-fungal therapy and inhaled/oral corticosteroids forming the basis of treatment [2, 4, 5]. Sensitisation to Aspergillus is associated with increased exacerbations in patients with COPD http://bit.ly/3i4LVD9